Emergency Awards RADx-RAD: Novel Biosensing for Screening, Diagnosis and Monitoring of COVID-19 From Skin and The Oral Cavity (R44 Clinical Trial Not Allowed)

0
283

Funding Opportunity ID:328569
Opportunity Number:RFA-OD-20-020
Opportunity Title:Emergency Awards RADx-RAD: Novel Biosensing for Screening, Diagnosis and Monitoring of COVID-19 From Skin and The Oral Cavity (R44 Clinical Trial Not Allowed)
Opportunity Category:Discretionary
Opportunity Category Explanation:
Funding Instrument Type:Grant
Category of Funding Activity:Education
Health
Income Security and Social Services
Category Explanation:
CFDA Number(s):93.121
93.233
93.273
93.286
93.307
93.310
93.350
93.837
93.838
93.839
93.840
93.846
93.865
93.879
Eligible Applicants:Small businesses
Additional Information on Eligibility:Other Eligible Applicants include the following: Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, may be allowed.
Agency Code:HHS-NIH11
Agency Name:Department of Health and Human Services
National Institutes of Health
Posted Date:Aug 06, 2020
Close Date:Sep 18, 2020
Last Updated Date:Aug 06, 2020
Award Ceiling:$0
Award Floor:$0
Estimated Total Program Funding:
Expected Number of Awards:
Description:The goal of this RFA is to solicit direct to Phase II SBIR proposals for development of novel, non-traditional, approaches to identify the current SARS-CoV-2 virus or other biomarkers of the COVID-19 disease for use in outbreaks of COVID-19, as well as for use in future pandemics resulting from unknown viruses. This FOA is seeking applications for innovative portable devices able to produce reliable associations between biomarkers emanating from skin and the oral cavity to patients with symptomatic and asymptomatic COVID-19. Specifically, biosensing devices are expected to target skin or the oral cavity as sampling sites. Skin biosensing must detect volatile organic compounds (VOCs, i.e. scents or odors) emanating from skin in passive and noninvasive manner for use at the point of care. In addition to VOCs, oral biosensing technologies may target a wealth of biological, chemical and physical biosignatures representative of COVID-19 that can be sampled from exhaled breath/droplets, saliva, and tissues in the oral cavity. Leveraging the accessibility of human skin and the oral cavity, this FOA seeks 1) to advance novel biosensing technologies that are innovative, safe, and effective, and 2) to implement such technologies into devices with integrated artificial intelligent (AI) systems for the detection, diagnosis, prediction, prognosis and monitoring of COVID-19 in clinical, community and everyday settings. For skin monitoring, the device can include Electronic-nose (E-nose) technology or Gas Chromatography (GC). Thus, we are calling this program, the SCENT (Screening for COVID-19 by E-Nose Technology). Biosensing devices for the oral cavity can be technologies that have been thoroughly characterized as safe and effective in preclinical studies. Non-invasive, real-time, continuous or periodic measurements of VOCs and other biomarkers in breath, and emanating from oral tissues as signatures of onset, progression, and resolution of COVID-19 are desirable.
Version:1





Visit the Official Webpage For More Details on Emergency Awards RADx-RAD: Novel Biosensing for Screening, Diagnosis and Monitoring of COVID-19 From Skin and The Oral Cavity (R44 Clinical Trial Not Allowed)

LEAVE A REPLY

Please enter your comment!
Please enter your name here